Axial Spondyloarthritis (AXSPA)

Global Axial Spondyloarthritis (AXSPA) Market to Reach US$8.4 Billion by 2030

The global market for Axial Spondyloarthritis (AXSPA) estimated at US$6.4 Billion in the year 2024, is expected to reach US$8.4 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Ankylosing Spondylitis, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Non-Radiographic Axial Spondyloarthritis segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 7.2% CAGR

The Axial Spondyloarthritis (AXSPA) market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Axial Spondyloarthritis (AxSpA) Market – Key Trends & Drivers Summarized

Why Is Axial Spondyloarthritis Gaining Visibility as a High-Burden Chronic Condition Requiring Early Diagnosis and Long-Term Therapeutic Management?
Axial spondyloarthritis (AxSpA) is drawing increased clinical and commercial focus as its prevalence and long-term impact on patient quality of life become more widely recognized. This inflammatory rheumatic disease primarily affects the spine and sacroiliac joints, manifesting as chronic back pain, stiffness, and reduced mobility. Despite its disabling nature, AxSpA remains underdiagnosed or misdiagnosed for years due to symptom overlap with non-inflammatory back pain and lack of early imaging-based confirmation.

The disease encompasses two subsets—radiographic AxSpA (ankylosing spondylitis) and non-radiographic AxSpA—both of which can progress toward spinal fusion and irreversible joint damage if not adequately managed. The burden on working-age adults is particularly significant, with functional impairment, fatigue, and associated comorbidities such as uveitis, psoriasis, and inflammatory bowel disease further compounding healthcare complexity. These factors underscore the need for early, accurate diagnosis and sustained access to disease-modifying therapies.

Growing awareness campaigns, improvements in MRI-based diagnostic protocols, and revised clinical guidelines from rheumatology societies are helping increase recognition of AxSpA across healthcare systems. As more patients are identified earlier in their disease journey, demand for effective long-term therapeutic solutions is rising. Payers and healthcare providers are increasingly treating AxSpA as a priority chronic condition requiring integrated care models, long-term monitoring, and outcome-driven therapy optimization.

How Are Biologic Therapies, Precision Diagnostics, and Treatment Guidelines Advancing Patient Outcomes in AxSpA?
Biologic therapies—particularly tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors—have become the cornerstone of AxSpA treatment for patients who do not respond adequately to NSAIDs. These agents not only reduce inflammation and alleviate symptoms but also help slow structural damage progression. IL-17 inhibitors, such as secukinumab and ixekizumab, are gaining traction due to their efficacy in both radiographic and non-radiographic forms of AxSpA, providing a targeted alternative for TNF-inadequate responders.

Precision diagnostics are advancing treatment decisions, with HLA-B27 genetic testing, MRI-based inflammation assessment, and biomarker profiling enabling earlier diagnosis and stratified care. As understanding of disease heterogeneity improves, rheumatologists are increasingly leveraging these tools to differentiate AxSpA from mechanical back pain and tailor treatment pathways. The ability to confirm diagnosis prior to visible radiographic changes is critical in initiating timely intervention and avoiding irreversible joint damage.

Updated treatment guidelines from entities such as ASAS, EULAR, and ACR are standardizing care approaches and encouraging early referral to specialists. Stepwise escalation protocols—starting with NSAIDs, moving to biologics upon inadequate response, and integrating physiotherapy and lifestyle modifications—are guiding clinical decision-making. These frameworks are helping align payer policies, reduce delays in access to advanced therapies, and improve long-term disease control in diverse healthcare settings.

Which Patient Demographics, Regional Dynamics, and Access Models Are Driving Therapeutic Demand in the AxSpA Market?
AxSpA primarily affects individuals in their 20s to 40s, a demographic that underscores its societal and economic impact due to reduced workforce participation, absenteeism, and long-term disability. Gender-related differences in presentation and disease progression are influencing diagnosis and treatment patterns, as women with non-radiographic AxSpA often present with atypical symptoms and face delayed diagnosis. This has catalyzed efforts to improve gender-sensitive screening and raise clinical suspicion among primary care providers.

Regionally, Europe and North America lead in diagnosis and treatment adoption, supported by specialist density, advanced diagnostic infrastructure, and broad access to biologics through public and private insurance systems. Asia-Pacific markets, particularly Japan and South Korea, are seeing increased diagnosis rates due to awareness campaigns and investment in rheumatology capacity. Emerging markets, while lagging in biologic accessibility, are expanding non-biologic treatment volumes and initiating government-funded pilot programs to enhance early detection and subsidized care.

Access models are evolving to address cost barriers associated with biologic treatment. Biosimilars are expanding therapeutic options at lower price points, enabling broader patient coverage and inclusion in national reimbursement schemes. Value-based pricing frameworks and risk-sharing agreements are being explored to align therapy costs with real-world outcomes. Meanwhile, patient assistance programs and digital health support tools are improving treatment adherence and enabling continuous disease monitoring in remote or underserved populations.

How Are Drug Development Pipelines, Digital Monitoring Tools, and Multimodal Care Models Shaping the Market Outlook?
The drug development pipeline for AxSpA is diversifying beyond TNF and IL-17 pathways, with investigational therapies targeting JAK-STAT signaling, GM-CSF inhibition, and novel cytokine pathways. Oral small molecules, in particular, are drawing attention for their ease of administration and potential to expand treatment to earlier stages or biologic-naïve populations. Clinical trials are increasingly stratifying by disease subtype, HLA-B27 status, and prior biologic exposure to better understand differential responses and optimize treatment sequencing.

Digital tools for symptom tracking, treatment adherence, and disease activity monitoring are enhancing patient engagement and enabling data-driven care models. Mobile apps, wearables, and AI-based decision support systems are being integrated into rheumatology workflows to track pain, stiffness, sleep disruption, and mobility over time. These platforms are supporting remote consultations, treatment adjustments, and early identification of disease flares—improving real-time management and long-term outcome tracking.

Multimodal care models that combine pharmacological treatment with physiotherapy, psychological support, and lifestyle interventions are gaining traction in both public and private healthcare systems. As the chronic and multifaceted nature of AxSpA becomes more apparent, care coordination between rheumatologists, physiatrists, psychologists, and primary care providers is being emphasized. These integrated models not only improve patient-reported outcomes but also reduce healthcare utilization and overall cost of care.

What Are the Factors Driving Growth in the Axial Spondyloarthritis (AxSpA) Market?
The AxSpA market is expanding as diagnostic precision, biologic innovation, and healthcare system awareness converge to reframe the condition as a manageable chronic disease with tangible long-term benefits from early and sustained treatment. The shift from underdiagnosis to proactive disease monitoring is enabling better patient stratification and therapy alignment.

Key growth drivers include rising prevalence among working-age populations, expanding access to biologics and biosimilars, global guideline harmonization, and increasing payer willingness to reimburse early-stage intervention. The integration of digital health tools and coordinated care models is further reinforcing market maturity and patient-centric innovation.

As chronic inflammatory diseases move to the forefront of healthcare priorities, could axial spondyloarthritis become a model for how early detection, precision therapy, and integrated care redefine long-term outcomes in autoimmune disease management?

SCOPE OF STUDY:

The report analyzes the Axial Spondyloarthritis (AXSPA) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Deutschland GmbH & Co. KG
• AbbVie Inc.
• Acelyrin, Inc.
• Affibody AB
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Biogen Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• Galapagos NV
• Gilead Sciences, Inc.
• GlaxoSmithKline plc (GSK)
• Inmagene Biopharmaceuticals
• Janssen Biotech, Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.